Solomon Moshkevich Sells 3,000 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $238.15, for a total value of $714,450.00. Following the completion of the transaction, the insider owned 109,061 shares in the company, valued at approximately $25,972,877.15. This trade represents a 2.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $198.60, for a total value of $595,800.00.
• On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The shares were sold at an average price of $191.46, for a total value of $229,369.08.
• On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The stock was sold at an average price of $192.32, for a total transaction of $193,858.56.
• On Tuesday, October 21st, Solomon Moshkevich sold 292 shares of Natera stock. The shares were sold at an average price of $187.95, for a total transaction of $54,881.40.
• On Wednesday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $159.99, for a total transaction of $479,970.00.

Natera Stock Performance

Shares of Natera stock traded up $1.57 during trading on Wednesday, reaching $238.21. The company had a trading volume of 1,576,193 shares, compared to its average volume of 1,627,628. The firm’s fifty day moving average is $196.35 and its 200-day moving average is $172.56. The company has a market cap of $32.88 billion, a price-to-earnings ratio of -104.02 and a beta of 1.63. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $241.28.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same period in the prior year, the firm posted ($0.26) EPS. The firm’s quarterly revenue was up 34.7% on a year-over-year basis. On average, research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on NTRA. JPMorgan Chase & Co. lifted their price objective on shares of Natera from $240.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 25th. BTIG Research lifted their price target on Natera from $210.00 to $230.00 and gave the company a “buy” rating in a report on Friday, November 7th. Cowen reissued a “buy” rating on shares of Natera in a research report on Friday, August 8th. Piper Sandler raised their price objective on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Finally, BNP Paribas Exane upgraded Natera from an “underperform” rating to a “neutral” rating and set a $172.00 target price on the stock in a report on Monday, October 27th. Fifteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $223.53.

Institutional Trading of Natera

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD grew its position in Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after purchasing an additional 3,795,315 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Natera by 44.3% during the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after acquiring an additional 3,263,822 shares during the period. Norges Bank acquired a new position in Natera in the 2nd quarter valued at approximately $277,749,000. Nuveen LLC bought a new stake in shares of Natera in the 1st quarter worth approximately $113,375,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Natera by 140.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company’s stock worth $177,298,000 after purchasing an additional 732,156 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.